Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity.
William C DougallAmelia Roman AguileraMark J SmythPublished in: Clinical & translational immunology (2019)
In summary, the bispecific anti-RANKL/PD-1 antibody demonstrates potent tumor growth inhibition in settings of ICI resistance and represents a novel modality for clinical development in advanced cancer.